Schweizerisch-Deutsches Erbrecht

Published: 12 February 2011
  • PEOPLE

Insights

Insights 27.08.2026

Swiss sanctions against Russia – Further alignment with the EU – Implementation of the 20th Sanctions Package

Swiss sanctions against Russia – Further alignment with the EU –…

<p>In a continued effort to align with European Union (“<strong>EU</strong>”) sanctions, on 19 August 2026, the Swiss Federal Council adopted additional measures transposing core elements of the EU’s 20<sup>th</sup> sanctions package (adopted at EU level on 23 April 2026). The Swiss amendments entered into force on <strong>20 August 2026</strong>, with certain measures phased in later in September 2026 and January 2027.</p> <p>The revision notably (i) removes, as from 1 September 2026, the sanctions-based restrictions on the sale, delivery and exportation of military equipment goods – as well as the associated financial services and brokerage restrictions – to Ukraine, (ii) introduces new prohibitions on services linked to LNG carriers, icebreakers and Russian LNG terminals, (iii) activates for the first time the “<strong>anti-circumvention tool</strong>”&nbsp;targeting exports of sensitive goods to Kyrgyzstan, (iv) expands prohibitions on transactions with Russian crypto-asset service providers and platforms, and (v) introduces new measures to protect Swiss companies against IP infringements and abusive Russian court decisions.</p>

Insights 04.08.2026

Switzerland steps up: Federal Patent Court affirms cross-border reach in patent litigation

Switzerland steps up: Federal Patent Court affirms cross-border reach in…

<p><strong>Switzerland as a forum for cross-border patent enforcement: the Federal Patent Court confirms its reach</strong></p> <p class="MsoBodyText">In a landmark decision of 17 July 2026 (S2025_003), the Swiss Federal Patent Court has sent a clear signal: Switzerland is very much in the game when it comes to cross-border patent enforcement. The Court confirmed that claims for infringement of foreign patent designations can be heard at the defendant’s Swiss domicile and established a powerful principle of parallel infringement analysis across all EPC member states. For patent holders pursuing multi-jurisdictional strategies, Switzerland must be on the map.</p> <p class="MsoBodyText">The case arose from interim proceedings brought by Regeneron Pharmaceuticals, Inc., Bayer HealthCare LLC and Bayer Consumer Care AG against Sandoz Group AG, Sandoz AG and Sandoz Pharmaceuticals AG. The claimants sought a pan-European injunction against the distribution of Sandoz’ aflibercept biosimilar, relying on both the Swiss designation and multiple foreign designations of a European patent. The case thus presented the Court with a textbook scenario for testing Switzerland’s credentials as a cross-border patent litigation forum.</p> <p class="MsoBodyText">The Court rose to the occasion, delivering clear guidance on two issues that matter for any cross-border patent strategy:</p>

SEE ALL